We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+43.32%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
+$297M
Cap. Flow
+$58.3M
Cap. Flow %
4.28%
Top 10 Hldgs %
45.16%
Holding
305
New
90
Increased
79
Reduced
51
Closed
35

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$31.8M
2
CLDX icon
Celldex Therapeutics
CLDX
+$14.2M
3
IVA
Inventiva
IVA
+$12.6M
4
TERN
Terns Pharmaceuticals
TERN
+$12.3M
5
ABUS icon
Arbutus Biopharma
ABUS
+$11.3M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$94.2M
2
ETNB
89bio
ETNB
+$31.1M
3
BIOA
BioAge Labs
BIOA
+$15.5M
4
MTSR
Metsera Inc
MTSR
+$7.98M
5
IVVD icon
Invivyd
IVVD
+$7.22M

Sector Composition

Rank Sector Weight
1 Healthcare 88.69%
2 Financials 1.72%
3 Real Estate 0.12%
4 Communication Services 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
176
Sarepta Therapeutics
SRPT
$1.77B
$621K 0.05%
28,866
-320,941
-92% -$6.76M
ISRG icon
177
Intuitive Surgical
ISRG
$134B
$578K 0.04%
+1,020
New +$543K
KYTX icon
178
Kyverna Therapeutics
KYTX
$481M
$540K 0.04%
+57,428
New +$426K
BABA icon
179
Alibaba
BABA
$307B
$524K 0.04%
3,578
– –
MDGL icon
180
Madrigal Pharmaceuticals
MDGL
$11.8B
$521K 0.04%
895
-4,000
-82% -$2.04M
CGEM icon
181
Cullinan Oncology
CGEM
$1.13B
$518K 0.04%
+50,000
New +$451K
CNTX icon
182
Context Therapeutics
CNTX
$44.8M
$516K 0.04%
351,094
– –
GTERU
183
Globa Terra Acquisition Corp Units
GTERU
$514K 0.04%
50,000
– –
USFR icon
184
WisdomTree Floating Rate Treasury Fund
USFR
$18.4B
$503K 0.04%
10,000
– –
APLS
185
DELISTED
Apellis Pharmaceuticals
APLS
$502K 0.04%
20,000
– –
NTRA icon
186
Natera
NTRA
$46B
$492K 0.04%
+2,147
New +$448K
BSX icon
187
Boston Scientific
BSX
$71.4B
$477K 0.04%
+5,000
New +$490K
ELVN icon
188
Enliven Therapeutics
ELVN
$4.41B
$462K 0.03%
+30,000
New +$598K
ELAN icon
189
Elanco Animal Health
ELAN
$11.1B
$453K 0.03%
+20,000
New +$435K
PYPD icon
190
PolyPid
PYPD
$92.8M
$451K 0.03%
+103,950
New +$386K
GERN icon
191
Geron
GERN
$956M
$444K 0.03%
336,176
-120,000
-26% -$151K
PRAX icon
192
Praxis Precision Medicines
PRAX
$9.92B
$442K 0.03%
+1,500
New +$279K
NVCR icon
193
NovoCure
NVCR
$1.9B
$440K 0.03%
34,000
– –
CORZ icon
194
Core Scientific
CORZ
$6.75B
$437K 0.03%
+30,000
New +$523K
OMER icon
195
Omeros
OMER
$952M
$429K 0.03%
+25,000
New +$215K
CTMX icon
196
CALL
CytomX Therapeutics
CTMX
$753M
$426K 0.03%
+100,000
New +$380K
KURA icon
197
Kura Oncology
KURA
$849M
$416K 0.03%
40,000
-15,000
-27% -$157K
VTGN icon
198
VistaGen Therapeutics
VTGN
$12.7M
$413K 0.03%
623,575
+510,513
+452% +$1.84M
BHVN icon
199
Biohaven
BHVN
$2.23B
$387K 0.03%
34,277
+9,936
+41% +$123K
KROS icon
200
Keros Therapeutics
KROS
$220M
$384K 0.03%
18,851
-5,370,413
-100% -$94.2M
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, ADAR1 Capital Management held 305 positions worth $1.36B, up 28% from $1.06B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

ADAR1 Capital Management deployed $58.3M of net new capital in Q4 2025, opening 90 new positions and adding to 79 existing holdings. Its largest new stake was Inventiva: 2,709,846 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier, followed by Financials and Real Estate.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $94.2M trimmed.

  • ADAR1 Capital Management's largest Q4 2025 buy was Inventiva: 2,709,846 shares worth $12.6M.
  • ADAR1 Capital Management added most to Avidity Biosciences in Q4 2025, an estimated $31.8M increase.
  • ADAR1 Capital Management's biggest Q4 2025 reduction was Keros Therapeutics, cutting an estimated $94.2M.
  • ADAR1 Capital Management fully exited 89bio in Q4 2025, selling an estimated $31.1M.
  • ADAR1 Capital Management's ten largest holdings make up 45% of its $1.36B portfolio in Q4 2025.
  • ADAR1 Capital Management opened 90 new positions and closed 35 in Q4 2025.
  • ADAR1 Capital Management's portfolio value rose 28% quarter-over-quarter to $1.36B.

Based on ADAR1 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.